pd 153035 has been researched along with Uterine Cervical Neoplasms in 2 studies
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.
Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woodworth, CD | 1 |
| Michael, E | 1 |
| Marker, D | 1 |
| Allen, S | 1 |
| Smith, L | 1 |
| Nees, M | 1 |
| Bos, M | 1 |
| Mendelsohn, J | 1 |
| Kim, YM | 1 |
| Albanell, J | 1 |
| Fry, DW | 1 |
| Baselga, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Histological Characterization and Differentiation of Rash From Other EGFR Inhibitors[NCT00709878] | 32 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00709878)
Timeframe: 6 months
| Intervention | Total number of cases (Number) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ulceration | Parakeratosis | Acanthosis | Epidermal atrophy | Epidermal dysmaturation | Epidermal dyskeratosis | Epidermal neutrophilc infiltrate | Epidermal monocytic infiltrate | Epidermal eosinophilic infiltrate | Dermal neutrophilic infiltrate | Dermal monocytic infiltrate | Dermal eosinophilic infiltrate | Follicular concretions | Follicular neutrophilic pustule | Dysmorphic follicle | Follicular dyskeratosis | Follicular neurtrophilic infiltrate | Follicular monocytic infiltrate | Follicular eosinophilic infiltrate | Eccrine dyskeratosis | Eccrine necrosis | Eccrine infiltrate | Sebaceous infiltrate | |
| Patients Treated With Cetuximab (C) | 1 | 2 | 1 | 5 | 3 | 3 | 1 | 0 | 0 | 0 | 4 | 2 | 5 | 4 | 2 | 3 | 5 | 2 | 1 | 1 | 2 | 0 | 1 |
| Patients Treated With Erlotinib (E) | 2 | 0 | 0 | 4 | 0 | 0 | 1 | 0 | 1 | 4 | 4 | 0 | 3 | 6 | 4 | 1 | 7 | 2 | 1 | 0 | 1 | 0 | 3 |
| Patients Treated With Lapatinib (L) | 1 | 1 | 1 | 7 | 2 | 3 | 1 | 0 | 0 | 2 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | 2 | 2 | 0 | 0 | 0 | 0 |
| Patients Treated With Panitumumab (P) | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 2 | 0 | 2 | 4 | 0 | 2 | 3 | 2 | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 1 |
2 other studies available for pd 153035 and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor | 2005 |
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Enzyme Inhibitors; Er | 1997 |